Clinical Trials Sponsored by Ipsen Biopharmaceuticals

Total 1115 results

Ipsen

Completed

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children (PUL)

Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

United States, Poland, Spain, Belgium, Israel, Turkey, Czechia, Mexico
Ipsen

Completed

Dysport® Adult Lower Limb Spasticity Follow-on Study

Post-stroke Spasticity | Spasticity Post-Traumatic Brain Injury

United States, Australia, France, Belgium, Hungary, Poland, Portugal, Slovakia, Czechia, Russian Federation, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Overactive Bladder | Urinary Incontinence

United States, Korea, Republic of, Czechia, Netherlands, Romania, Poland, Turkey, Portugal, Canada, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
Ipsen

Completed

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Cervical Dystonia

France, Belgium, Czechia, Australia, Poland, Portugal, Ukraine, Hungary, Russian Federation, Austria, Germany
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Ipsen

Completed

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma (CASSIOPE)

Renal Cell Carcinoma

Germany, Spain, Italy, Greece, Belgium, France, Netherlands, United Kingdom, Austria, Czechia, Poland
Ipsen

Completed

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Neuroendocrine Tumours (NET)

United Kingdom
Ipsen

Completed

Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA (RETURN)

Spasticity

Brazil
Ipsen

Terminated

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

Pancreatic Neuroendocrine Tumor

Spain, Portugal
Ipsen

Completed

Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy (EASYKID)

Digestive System Disease

Czechia, France, Germany, Poland, Netherlands, Italy
Ipsen

Completed

Dysport in Post-Surgical Neuralgia (PMOD03)

Chronic Scar Pain

United Kingdom
Ipsen

Completed

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Lower Limb Spasticity

United States
Ipsen

Terminated

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Primary Insulin-like Growth Factor-1 Deficiency

United States
Ipsen

Completed

To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke (ULIS2)

Muscle Spasticity

Australia, Austria, Belgium, China, Czechia, Denmark, Finland, France, Germany, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Portugal, Russian Federation, Singapore, Spain, Sweden, Taiwan, Thailand, United Kingdom
Ipsen

Completed

Phase IV-Cervical Dystonia-INTEREST IN CD2 (INTEREST_INCD2)

Cervical Dystonia

Korea, Republic of, Thailand, Belgium, Israel, Taiwan, Germany, Hungary, United States, Singapore, Slovenia, United Kingdom, Australia, Malaysia, Serbia, Estonia, Turkey, Italy, Poland, China, Sweden, Portugal, Algeria, Austria, Brazil, Czechi... and more
Ipsen

Completed

Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults (ADIASE)

Acute Diarrhoea

Egypt, Algeria, Czechia, Lebanon, Poland, Tunisia
Ipsen

Completed

A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

Advanced Renal Cell Carcinoma

United Kingdom
Ipsen

Completed

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours (QUALINETS)

Gastrointestinal Neuroendocrine Tumours

Spain, Portugal
Ipsen

Terminated

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

Austria
Ipsen

Completed

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

Growth Disorders | Insulin-Like Growth Factor-1 Deficiency

United States
Ipsen

Completed

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours (STREET)

Gastroenteropancreatic Neuroendocrine Tumours

Sweden
Ipsen

Withdrawn

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly (PLAN-A)

Acromegaly
Ipsen

Completed

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
Ipsen

Completed

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Chronic Constipation

Thailand
Ipsen

Completed

Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis

Migraine

Czechia, Poland, Slovakia
Ipsen

Completed

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

Friedreich Ataxia

France
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
Ipsen

Completed

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer (DKP 3M SC)

Prostate Cancer

Poland, Romania, Bulgaria, Latvia, France
Ipsen

Completed

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Triple Negative Breast Cancer | Solid Tumors | ER/PR Positive Breast Cancer | Metastatic Breast Cancer With Active Brain Metastasis

United States
Ipsen

Completed

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Acromegaly

Germany
Ipsen

Terminated

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients (POSEIDON)

Prostate Cancer

Italy
Ipsen

Completed

BN83495 Phase I in Post-menopausal Women

Breast Cancer

France, United Kingdom, Belgium
Ipsen

Completed

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

Lateral Canthal Lines

France, Germany, United Kingdom
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Completed

Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis

Chronic Plantar Fasciitis

Germany
Ipsen

Terminated

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Overactive Bladder

United Kingdom, Spain, Netherlands, Belgium, France, Germany, Czechia, Italy
Ipsen

Completed

Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome

Myofascial Pain Syndromes

Italy, Spain, Portugal, Czechia, Germany, Poland
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Completed

Validation of Patient Reported Outcome Measures for Use in Vulvodynia

Vulvodynia

United States
Ipsen

Terminated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer (ANABRAQ)

Prostate Cancer

Spain
Ipsen

Completed

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Renal Cell Carcinoma | Renal Cell Carcinoma Metastatic

Taiwan
Ipsen

Completed

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

Cervical Dystonia

United States
Ipsen

Completed

Description of Sign-and-symptom Associations at Acromegaly Diagnosis. (ACRO-POLIS)

Acromegaly

France
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice (ULIS III)

Upper Limb Spasticity

Taiwan, United States, Germany, Australia, Hong Kong, Philippines, France, Russian Federation, Italy, Portugal, Brazil, Austria, Mexico, Poland
Ipsen

Completed

Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm

Muscle Spasticity | Cerebrovascular Accident

Australia
Ipsen

Completed

A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.

Myofascial Pain Syndromes

Korea, Republic of
Ipsen

Completed

Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity

Muscle Spasticity | Cerebrovascular Accident

Hong Kong, Thailand, Malaysia, Philippines, Singapore
Ipsen

Completed

Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain

Low Back Pain

Korea, Republic of

3

Subscribe